NCI Definition [1]:
A monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. CSF1R monoclonal antibody IMC-CS4 binds to CSF1R which may trigger antitumoral antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells overexpressing CSF1R. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (Cluster of Differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1); this receptor is overexpressed or mutated in certain tumor cell types and plays major roles in tumor cell proliferation and metastasis.

Imc-cs4 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating imc-cs4, 1 is early phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).

BRAF V600E and BRAF V600K are the most frequent biomarker inclusion criteria for imc-cs4 clinical trials.

Melanoma and pancreatic adenocarcinoma are the most common diseases being investigated in imc-cs4 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Imc-Cs4
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating imc-cs4 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ly3022855, anti-csf-1r monoclonal antibody imc-cs4, anti-csf1r monoclonal antibody imc-cs4
Drug Target(s) [2]:
NCIT ID [1]:


1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.